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Abstract p73, the gene for a protein related to the tumor
suppressor p53, encodes several variants which bear distinct
carboxy-terminal structures as a result of alternative splicing.
We and others showed that these splicing variants have different
transcriptional effects on promoters with a p53-binding con-
sensus sequence (p53BCS). Here we show that when transiently
overexpressed, p73K but not p73L activated several minimal
promoters without the p53BCS, while p73Q and p73O activated
them to a much lesser extent than p73K, and p53 suppressed the
promoters without p53BCS as reported previously. Moreover,
the results of RNase protection and RNA transfection assays
suggested that this activation occurred at the transcriptional
level. Deletion analysis of p73K revealed that the transactivation
domain of p73 was not involved in this activity and the C-
terminal region of p73K which is a specific structure of this
variant was essential, suggesting that this phenomenon occurs
independent of the transactivation activity of p73K and that the
C-terminal extension of p73K may affect the basal level of
transcription. ß 2001 Published by Elsevier Science B.V. on
behalf of the Federation of European Biochemical Societies.
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1. Introduction
The p73 gene was identi¢ed as a gene encoding a protein
homologous to the tumor suppressor p53 [1]. mRNAs for p73
variant proteins, K, L, Q, N, and O, which bear distinct carboxy-
terminal structures, have been shown to be produced from a
single gene as a result of alternative splicing [2,3]. We and
others revealed that these splicing variants di¡er in potential
for the transcriptional activation of p53-responsive promoters
[2,3]. Extensive homology between all the p73 variants and
p53 was found within conserved p53 domains for transactiva-
tion, DNA-binding, and oligomerization [1]. Functional sim-
ilarities were also observed between p73 and p53. When over-
produced, just like p53, p73K and L can activate transcription
from p53-responsive promoters of several genes including the
gene for p21/WAF1, an inhibitor of cyclin-dependent protein
kinases [4]. Overproduction of p73K was also observed to
promote apoptosis, as in the case of p53 [4,5]. For the ¢rst
time, p73 was suggested to be a tumor suppressor because of
the similarities to p53 mentioned above. This idea seemed to
be supported by the fact that the p73 gene was mapped to the
chromosomal region at 1p36.33, frequently deleted in a vari-
ety of cancers including neuroblastomas, breast carcinoma
and colon carcinoma [1,6,7]. However, some functional diver-
sity does exist between p73 and p53. In many tumor cells, a
mutation in p73 is seldom found [8]. p53 protein, which is
degraded rapidly by the proteasome through the ubiquitina-
tion pathway under non-stressed conditions, is known to be
accumulated and activated in response to genotoxic stress,
inducing cell growth arrest or apoptosis [9,10]. However,
p73 was not accumulated in response to genotoxic stress
such as UV irradiation or administration of actinomycin D
[1]. p73 was recently found to be stabilized and activated on
treatment with another genotoxic reagent, cisplatin, through
the activation of tyrosine kinase c-Abl [11,12]. And the viral
proteins adenovirus E1B 55K, simian virus 40 (SV40) T anti-
gen, and human papillomavirus E6, which are known to bind
with and inactivate p53, did not have any e¡ect on p73
[13,14]. Moreover, p73 knock-out mice did not show an in-
creased susceptibility to spontaneous tumorigenesis in con-
trast to p53-de¢cient mice [15]. We recently reported that
p73L but not p53 activates the Wnt/L-catenin signaling path-
way in Saos-2 cells [16].
During a previous study on the transcriptional activities of
p73 splicing variants, we found that p73K, Q and O but not L
enhanced the luciferase activity from the reporter plasmid,
p55Bluc, which contains an interferon L basal promoter ele-
ment without apparent homology to the p53-binding se-
quence. This seemed to be another di¡erence between p73
and p53, because when overexpressed, p53 has been shown
to suppress transcription from several viral and cellular pro-
moters without the p53-responsive element, such as SV40
early promoter, cytomegalovirus immediate-early promoter,
human immunode¢ciency virus long terminal repeat, and pro-
moters of the gene for multiple drug resistance and heat shock
protein 70 [17^19]. Recently, Deb et al. showed that p73K but
not p73L activated the promoter of the insulin-like growth
factor receptor I (IGF-I-R) gene, which was shown to be sup-
pressed by p53 [20]. Given our previous ¢nding, we speculated
that the expression of p73K a¡ects the activity of the minimal
transcriptional promoter. Therefore, we analyzed several min-
imal promoters without p53-binding consensus sequence
(p53BCS) and determined whether their activation occurred
at the transcriptional level. Furthermore, we also show the
structural requirement of p73K for this activity using the other
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p73 splicing variants and deletion mutants of p73K and dis-
cuss the possible mechanisms and functional implications.
2. Materials and methods
2.1. Cell culture
Saos-2 cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
(Nissui) supplemented with 10% fetal bovine serum and L-glutamine
(584 Wg/ml) at 37‡C in a 5% CO2 atmosphere.
2.2. Plasmids and transient transfections
Expression plasmids, pcDNA3-p73K, L, Q, O, and pcDNA3-p53 as
well as pcDNA3-Myc-p73K, L, Q, O, and pcDNA3-Myc-p53 were de-
scribed previously [3,21]. Expression plasmids for the deletion mutants
of p73s, pcDNA3-p73vN56,vN130,vN315,vN423,vC505,vC424 and
p73LvOD, were constructed by a polymerase chain reaction (PCR)-
based cloning technique using pcDNA3-p73K and pcDNA3-p73L as
templates. All these constructs were veri¢ed by sequencing. pGL3-
Promoter was purchased from Promega. Reporter plasmids,
p55Bluc and pCAST2Bluc, were kindly provided by Dr. T. Kiyono
(Aichi Cancer Center Research Institute, Nagoya, Japan). For plas-
mid transfection, we used FuGENE6 transfection reagent (Roche)
according to the manufacturer’s protocol.
2.3. Synthesis of luciferase RNA and RNA transfection
pGEM-luc vector (Promega) digested with XhoI was transcribed
using a MEGAscript SP6 kit (Ambion) in the presence of
m7(5P)ppp(5P)G (cap analog, Ambion). The transfection of synthetic
RNA into Saos-2 cells was done using DMRIE-C reagent (Invitrogen)
for 3 h, after which the transfection medium was changed to fresh
culture medium. After being cultured for 24 h, the cells were harvested
and used as samples for the reporter assay.
2.4. Reporter assay
Cell extracts were prepared in Reporter Lysis Bu¡er (Promega) 24 h
after transfection. After the removal of cell debris, the luciferase ac-
tivity in the extracts was measured with a luciferase assay kit (Prom-
ega) using a luminometer (Berthold, Lumat LB 9507) as recom-
mended by the manufacturers.
2.5. Immunoblot analysis
Whole cell extracts were prepared 24 h after transfection. Sodium
dodecyl sulfate^polyacrylamide gel electrophoresis and immunoblot-
ting analysis using a polyvinylidene di£uoride membrane were per-
formed as described previously [22]. The antibody used in these ex-
periments was anti-c-Myc (9E10) (Santa Cruz Biotechnology).
2.6. Ribonuclease protection assay
Total RNA was isolated from the cells 24 h after transfection of the
expression and reporter plasmids by Sepasol-RNA I (Nacalai tesque).
To obtain the expression plasmids for the antisense RNA probes,
pcDNA3-AS-luc and pcDNA3-AS-hGAPDH (human glyceralde-
hyde-3-phosphate dehydrogenase) were generated as follows;
pcDNA3-AS-luc was constructed by inserting the EcoRI^XhoI frag-
ment of a PCR product, which had been ampli¢ed by using the
pGL3-Promoter as a template and oligonucleotides 5P-GGGCTCGA-
GATGGAAGACGCCAAAAACA-3P and 5P-CCGGAATTCCCTC-
GATATGTGCATCTGT-3P as primers, into the EcoRI^XhoI site of
pcDNA3. pcDNA3-AS-hGAPDH was constructed by inserting the
EcoRI^XhoI fragment of a reverse transcription-PCR product, which
was ampli¢ed using a One Step RNA PCR kit (TaKaRa) with prim-
ers 5P-TTTCTCGAGATGGGGAAGGTGAAGGTCG-3P and 5P-
CCGGAATTCTGGAGGGATCTCGCTCCTG-3P. The probe for
GAPDH mRNA was used as an internal control of mRNA. 32P-
labeled antisense RNA probes for detection of luciferase and GAPDH
mRNAs were prepared with a MEGAscript T7 in vitro transcription
kit (Ambion) and [K-32P]UTP (Amersham Pharmacia Biotech Inc.)
using pcDNA3-AS-luc and pcDNA3-AS-hGAPDH after linearization
by digestion with XhoI. These probes were hybridized with the total
RNA at 37‡C overnight. After digestion with RNase Cocktail (Direct
Protect, Ambion) for 30 min at 37‡C, these samples were separated in
5% acrylamide/8 M urea gel and then by autoradiography. The auto-
radiogram on the imaging plate was analyzed with a BAS 5000 (Fuji
Film).
3. Results
3.1. Enhanced luciferase activity from reporter plasmids
without a p53-binding site in cells overproducing p73K
To investigate the e¡ects of p73 splicing variants on the
promoters without the p53BCS, p55Bluc reporter plasmid
having the interferon L gene basal promoter was co-trans-
fected with an expression plasmid for p73 splicing variant
into Saos-2 cells, which do not produce p53 protein (Fig.
1A). We observed that the production of p73K induced a 6-
fold increase in luciferase activity compared to mock trans-
fection (Fig. 1B, closed bars). p73Q and O also raised the level
of luciferase activity 2-fold and 1.4-fold, respectively, although
these e¡ects may be marginal (Fig. 1B, closed bars). However,
no signi¢cant e¡ect on reporter activity was seen in the cells
producing exogenous p73L. On the other hand, expression of
p53 resulted in the suppression of reporter luciferase activity
compared with the control (Fig. 1B). This e¡ect of p53 has
been reported to be due to repression of transcription under
the control of the promoters with a TATA sequence [23].
Similar results were obtained using the reporter plasmids
pGL3-Promoter and pGL3-TK containing SV40 early pro-
moter and herpes simplex virus thymidine kinase gene pro-
moter, respectively, upstream of a luciferase gene (data not
shown), indicating that this result was not speci¢c for the
reporter plasmid p55Bluc.
To rule out the possibility that these results re£ect the dif-
ferent production levels of each protein, we examined the
correlation between reporter expression from p55Bluc and
production of the protein by titrating the amounts of plasmids
for p53, p73K, and p73L in transfection experiments. In-
creased production of each protein was con¢rmed by immu-
noblot analysis as shown in Fig. 1C. Under the conditions,
reporter expression a¡ected by p73K or p53 was observed to
be dependent on production levels (Fig. 1C), while the aug-
mented production of p73L caused no change in the reporter
expression. These results indicated that the di¡erence ob-
served between the e¡ect of p73K and p73L on p55Bluc was
not due to a quantitative di¡erence but to the potential of
each protein.
As the major structural di¡erence between p73K and L is
the extra C-terminal region of p73K, it would appear that this
region contributes to the augmentation by p73K of the report-
er expression from p55Bluc.
To see whether the above phenomenon occurs in other cell
lines, a reporter assay using p73K expression plasmid and
p55Bluc was performed in Jurkat cells lacking wild-type p53
and HepG2 cells and MCF-7 cells which are known to pro-
duce wild-type p53. The activation of reporter expression by
exogenous p73K was observed in all these three cell lines (data
not shown). This result showed that the e¡ect of p73K was
reproduced in several di¡erent cell lines and was independent
of the production of endogenous wild-type p53.
We previously reported that p73 splicing variants have dif-
ferent potentials to activate p53-binding element-dependent
transcription by using the reporter plasmid pCAST2Bluc con-
taining two copies of p53BCS upstream of the interferon L
basal promoter ([3] and Fig. 1B, open bars). The expression of
p73L induced markedly high luciferase activity as did p53.
p73Q activated the protein more than p73K. And p73O showed
no signi¢cant e¡ect on the activity of the promoter with
p53BCS. This implies that the e¡ects of p73 splicing variants
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on the expression of the reporter gene driven by the promoter
without p53BCS are independent of their potential for activa-
tion of the promoter with p53BCS.
3.2. Quantitative elevation of the reporter mRNA level
promoted by production of p73K
To assess whether the induction of luciferase activity by
p73K was caused by an increase in its mRNA level, a quanti-
tative analysis was performed using the RNase protection
assay to compare the luciferase mRNA levels in Saos-2 cells
transfected with pGL3-Promoter together with an expression
vector for p73K or p53, or an empty vector. As shown in Fig.
2A, the amount of luciferase mRNA in exogenous p73K-pro-
ducing cells was larger than that in mock-transfected cells
(lanes 4 and 5), while the expression of luciferase mRNA
was downregulated in the cells ectopically producing p53
(lane 6). These results suggested that the induction of lucifer-
ase activity by p73K was due to the elevated levels of this
reporter mRNA. Possible mechanisms for the accumulation
of mRNA would be transcriptional activation and/or promo-
tion of mRNA stability. To see whether the stability of lucif-
erase mRNA is changed by p73K or p53, we examined the
luciferase activity originating from transfected luciferase
mRNA transcribed in vitro in Saos-2 cells expressing p73K
or p53. However, no di¡erence in activity was observed be-
tween the cells (Fig. 2B, closed bars). These results indicated
that the increase in luciferase mRNA caused by p73K was not
due to the prolonged life span of the mRNA, suggesting that
this phenomenon occurred at the transcriptional level.
3.3. Structural requirement of p73K for activation of promoter
without p53BCS
To determine the domain(s) involved in the p73K-mediated
transcriptional activation of the promoter without p53BCS, a
deletion analysis of p73K coupled with the reporter assay was
performed as described in Section 2. Production of each trun-
cated protein in Saos-2 cells was detected by immunoblot
analysis (data not shown). Among the amino-terminal dele-
tion mutants, vN56 lacking the putative transactivation do-
main was found to induce the luciferase activity as e¡ectively
as wild-type p73K. vN315 in which the large N-terminal por-
tion of p73K is absent was also observed to induce the lucif-
erase activity more than mock transfection. However, the oth-
er N-terminal and all C-terminal deletion mutants did not
show any enhancement of promoter activity (Fig. 3A,B).
Although some di¡erences in the production levels were found
among the exogenous p73K derivatives, no correlation be-
tween the magnitude of reporter gene induction and the pro-
duction level of each protein was observed (data not shown),
indicating that the activities of the deletion mutants on the
reporter gene expression were dependent on the properties of
those proteins. These results suggested that a putative trans-
activation domain is not crucial for the induction of the re-
porter expression and almost all structures except the N-ter-
minal end of p73K are necessary for complete activity. It was
also likely that the C-terminal region of p73K plays an essen-
tial role in this activation. To con¢rm that a large part of
Fig. 1. Overproduced p73K but not p73L enhanced luciferase activ-
ity from a reporter plasmid without p53BCS. A: Schematic repre-
sentation of reporter plasmids. p55Bluc and pCAST2Bluc containing
the ¢re£y luciferase gene as a reporter gene were used as reporter
plasmids. Interferon L BP and 2Up53BCS indicate the basal pro-
moter of the interferon L gene and a tandem repeat of the p53BCS,
respectively. B: Transactivation capacities of p73 variants in the re-
porter plasmids, p55Bluc and pCAST2Bluc. Luciferase activity in
Saos-2 cells transfected with 1 Wg of expression plasmid for p73
splicing variants (pcDNA3-p73K, L, Q, and O), pcDNA3-p53 or
pcDNA3 vector only (shown as v) together with 0.3 Wg of p55Bluc
(closed bars) or pCAST2Bluc (open bars) was measured as de-
scribed in Section 2. Fold activation of the luciferase activity rela-
tive to that from the cells transfected with each reporter plasmid
and pcDNA3 vector was calculated and shown with the scale on
the left for p55Bluc and right for pCAST2Bluc. The data represent
the average of three independent experiments and are shown with
the standard error. C: Dose e¡ects of p73K on the reporter expres-
sion from p55Bluc in Saos-2 cells. Increasing amounts of pcDNA3-
Myc-p53, p73K or L (0 Wg: lanes 1, 6 and 11; 0.1 Wg: lanes 2, 7
and 12; 0.5 Wg: lanes 3, 8 and 13; 1.0 Wg: lanes 4, 9 and 14; 1.5
Wg: lanes 5, 10 and 15) were transfected into Saos-2 cells together
with 0.5 Wg of p55Bluc. The total amount of plasmid DNA used
for transfection was adjusted to 2 Wg by adding an appropriate
amount of empty vector pcDNA3. Luciferase activity was measured
and the data are presented. Expression levels of Myc-tagged pro-
teins were determined by immunoblotting using anti-c-Myc antibody
as shown in the lower panel.
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p73K is required for the activity observed in this paper, the
promoter activation potentials of several C-terminal polypep-
tides were examined in the presence of p73L, which did not
activate the basal promoter by itself. In this experiment, C-
terminal peptide was expected to form a complex with p73L in
an oligomerization domain-dependent manner for the follow-
ing reasons. First, analysis of the amino acid sequence sug-
gested that there exists an oligomerization domain in the pri-
mary structure of p73 as well as p53 [1]. Second, interaction
between p73 splicing variants through the oligomerization do-
main has been shown [21,24].
When the C-terminal polypeptide of p73vN315 containing
the oligomerization domain was produced together with p73L,
the basal promoter activity of pGL3-Promoter was apparently
increased (Fig. 3C, lane 6). Notably, the reduced activity of
p73v315 was seen to be completely recovered by coproduction
of p73L to the level equivalent to the potential of p73K. On
the other hand, when the C-terminal polypeptide of
p73vN423 lacking the oligomerization domain was copro-
duced with p73L, basal promoter activity was not seen to be
a¡ected (Fig. 3C, lane 7). Furthermore, when p73LvOD, in
which the oligomerization domain was deleted, was produced
with the above C-terminal polypeptides of p73K, no augmen-
tation of basal promoter activity was detected (Fig. 3C, lanes
8^10). As p73L has almost an identical structure to the C-
terminal deletion mutant of p73K, these results further sup-
ported the idea that the C-terminal region of p73K is essential
for the activation of pGL3-Promoter, and the region including
p73L is required for the complete activity.
4. Discussion
In this report, we have shown that p73K, when overpro-
duced in cultured cells, activates certain transcriptional pro-
moters without p53BCS. The mechanism of the activation by
p73K is likely to be di¡erent from that of the p73K-dependent
activation of the promoter with p53BCS for the following
reasons. First, p73vN56, lacking the transactivation domain,
still had the capacity to enhance the expression of reporter
genes from p55Bluc and pGL3-Promoter containing interfer-
on L and SV40 early promoters, respectively, similar to wild-
type p73K, although this truncated p73K did not show any
activation of the promoter with p53BCS of pCAST2Bluc (Fig.
3B and data not shown). Second, despite the transcriptional
activity of the promoter with p53BCS, p73vC424, which lacks
the C-terminal 213 amino acids of p73K, did not show any
activation of promoters without p53BCS ([3] and Fig. 3C).
This also seems to imply that the product(s) of the gene(s)
which is induced by p73K through p53BCS in its promoter is
not involved in this phenomenon.
The idea that the molecular interaction between p73 and a
particular transcriptional regulatory factor a¡ects the basal
transcriptional activity is one likely explanation for this phe-
nomenon. Transcriptional factors including p73 and p53 have
been known to function through interactions with other tran-
scriptional factors or with transcriptional regulatory factors
such as coactivators and corepressors [25^30]. Concerning
p53-dependent inhibition of promoters without p53BCS, it
has been suggested that this transcriptional factor binds
with the TATA-binding protein and sequesters it from other
transcriptional factors [31]. Recently, Murphy et al. also
showed that transcriptional repression in MAP4 and Stathmin
gene promoters was mediated through interaction with a co-
repressor, mSin3a [28]. These reports suggested that the re-
pression of promoters without p53BCS by p53 is mediated by
interactions between p53 and cellular proteins, especially tran-
scriptional factors or transcriptional regulatory factors. Be-
cause p73K has signi¢cant structural homology with p53, it
seems reasonable that p73K shares interacting counterparts
with p53. In fact, p73K was reported to utilize CREB-binding
Fig. 2. p73K a¡ected the production level of the reporter mRNA. A: An increase in the amounts of reporter mRNA caused by p73K was de-
tected by RNase protection assay. Total RNA of Saos-2 cells transfected with pGL3-Promoter and pcDNA3, pcDNA3-p73K, or pcDNA3-p53
(lanes 4^6) was isolated 24 h after transfection and used for RNase protection assay. 32P-labeled RNA probes for luciferase and GAPDH
mRNAs were prepared as described in Section 2. Detection of GAPDH mRNA was used for a loading control. The open arrowhead and open
arrow indicate 32P-labeled anti-GAPDH probe and 32P-labeled anti-luciferase probe, respectively, without RNase treatment (lane 1). After
RNase treatment without addition of total RNA, these probes were completely digested (lane 2). The closed arrowhead and closed arrow indi-
cate protected anti-GAPDH and anti-luciferase probes, respectively, after RNase treatment. Luciferase RNA transcribed in vitro was used as a
positive control (lane 3). B: p73K did not a¡ect the luciferase activity from the luciferase RNA transfected into Saos-2 cells. Saos-2 cells were
transfected with 1 Wg of pcDNA3, pcDNA3-Myc-p73K or pcDNA3-Myc-p53. At 24 h after plasmid transfection, cells were transfected with lu-
ciferase RNA which was transcribed in vitro as described in Section 2. Then, 24 h after RNA transfection, luciferase activity was measured
(closed bars). Plasmid-based reporter assay was performed essentially as described in Fig. 1B. The values shown for the luciferase assays repre-
sent the average of three independent experiments. Error bars represent the standard error.
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protein/p300 as a coactivator just like p53 for the activation of
promoters with p53BCS [25]. However, some di¡erences exist
between p73K and p53 in terms of protein^protein interac-
tions. For example, adenovirus E1B 55K, human papilloma-
virus E6 and SV40 T antigen, which are well known to bind
with and inactivate p53, have not been reported to associate
with p73K [13]. While it has been shown that human murine
double minute clone 2 oncoprotein (MDM2) binds to p53 and
promotes its degradation [32], it was also revealed that
MDM2 does not play a role in the degradation of p73K in
spite of molecular interaction [33]. In this report, the C-termi-
nal region of p73K was suggested to be important for activa-
tion of promoters without p53BCS. That region, which was
not found in the other splicing variants of p73 and p53, has
striking structural similarity with the SAM (sterile K motif)
domain [34], which is proposed to function in protein^protein
interaction [35]. Moreover, this C-terminal extension of p73K
was proposed to contribute to the interaction with several
proteins through small ubiquitin-related modi¢er 1 modi¢ca-
tion [36]. These ¢ndings suggested that p73K has the potential
to a¡ect certain cellular events through its molecular interac-
tion with cellular proteins that do not associate with p53 or
the other p73 splicing variants. It has been reported that hep-
atitis B virus (HBV) X protein (HBx) activates transcription
through protein^protein interaction. In that case, HBx was
considered to interact with RNA polymerase II subunit 5
(RPB5) and inhibit binding of RPB5 with RPB5-mediating
protein, a transcriptional corepressor. As a result, the tran-
scriptional promoter was suggested to be activated by a re-
duction in the amount of the corepressor from the transcrip-
tional machinery [37]. Therefore, it may be possible that p73K
modulated the function of the transcriptional corepressor(s)
through protein^protein interaction, just like HBx. Identi¢ca-
tion of the factor interacting with the C-terminal region of
p73K should provide important information on the molecular
mechanism of this phenomenon.
During the preparation of this paper, Doish et al. reported
that p73K enhanced HBV enhancer/promoter activity in con-
trast to p53 [38]. Deb et al. also reported that p73K but not
p73L activated the promoter of the IGF-I-R gene, which was
previously reported to be repressed by p53, in a transient
transfection reporter assay [20]. These observations may be
related with the ¢ndings of the present study. Further analysis
of the mechanism for the activation of promoters without
p53BCS by p73K will provide information on the physiolog-
ical function of this protein and the transcriptional mecha-
nism of p73 which is di¡erent from that of p53.
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